CA 19-9 (Cancer antigen 19-9)

P=N/A, N=3500, Active, not recruiting, Queen Mary University of London | Recruiting --> Active, not recruiting

Future directions include multicenter prospective trials to validate multimodal models, standardize detection methods, and increase interdisciplinary collaboration. By integrating genomic, epigenetic, metabolic, and microbiome data, these models can better capture the complexity of PDAC, thereby improving patient outcomes through precision immunotherapy.

The patient completed six cycles of adjuvant chemotherapy with tegafur-gimeracil-oteracil (S-1) plus oxaliplatin, and routine follow-up examinations showed no evidence of recurrence...The patient was treated with SOX chemotherapy combined with the PD-1 inhibitor tislelizumab...This case highlights the importance of vigilance for rare metastatic sites, such as the adrenal gland, in patients with advanced gastric cancer even after standardized postoperative surveillance. Systemic chemotherapy combined with immunotherapy may represent an effective treatment strategy for selected patients with metastatic gastric cancer.

Preoperative IBI and MAR are robust prognostic indicators in gastric cancer. The developed nomogram provides a practical visual tool for individualized postoperative risk assessment and management.

Giant splenic cysts accompanied by elevated CA19-9 levels are rare and pose a diagnostic challenge. Laparoscopy-assisted splenectomy offers a safe and effective approach for complete resection while minimizing the risk of intraoperative rupture and spillage.

Notably, baseline NR3C1 methylation levels predicted response to first-line FOLFIRINOX-based treatment with an acceptable 75% sensitivity and a high specificity of 92.86%. These findings highlight the clinical significance of cfDNA methylation as a minimally invasive biomarker source, emphasizing LAX1, NR3C1, and RCAN3 as prognostic biomarkers in mPDAC. Specifically, baseline NR3C1 methylation emerges as a promising predictor of treatment response, supporting personalized therapeutic strategies in mPDAC.

The patient underwent multimodal comprehensive treatment, including iodine-125 seed implantation at the pancreatic primary site, eight cycles of hepatic arterial infusion chemotherapy, PD-L1 inhibitor (Benmelstobart), and oral S-1 maintenance therapy. After treatment, the patient's liver metastases significantly decreased in size (partial response according to RECIST 1.1), CA19-9 levels dropped from 4141.57 U/mL to 58.64 U/mL, overall survival exceeded 15 months, and quality of life remained good (ECOG score 1). The MDT strategy, particularly the combination of local interventional therapy with systemic treatment and immunotherapy, can effectively control both the primary and metastatic lesions of advanced PDAC, significantly prolonging patient survival and providing valuable treatment references for similar cases.

Current literature indicates the widespread use of pancreaticoduodenectomy; while the role of chemotherapy remains unclear. The online version contains supplementary material available at 10.1007/s13691-026-00852-8.

Combined analysis improved performance (AUC = 0.95; sensitivity = 92%; specificity = 89%). Targeted serum nucleoside profiling enhances CRC detection and improves diagnostic accuracy when integrated with conventional tumor markers.

SL is safe and effective in determining accurate staging, which may allow for more appropriate treatment. Therefore, SL is actively recommended for patients with R PDAC or BR PDAC who are planning to undergo complete resection shortly to avoid unnecessary surgical exploration, especially those CEA positive or with CA19-9 ≥ 150 U/mL.

Ovarian teratomas may be associated with suspected cases of isolated autoimmune psychosis, even in the absence of typical neurological signs or positive autoantibodies. In such instances, CA19-9 elevation could serve as a nonspecific clue. Comprehensive imaging remains crucial for patients with atypical, treatment-resistant psychosis to avoid diagnostic delays.